ARTICLE | Clinical News
Zelboraf vemurafenib regulatory update
March 17, 2014 7:00 AM UTC
Germany's Federal Joint Committee (G-BA) said in a planned reassessment that Zelboraf vemurafenib from Roche has "significant" additional benefit vs. dacarbazine to treat melanoma. The assessment is i...